Skip to Content

Revance Therapeutics, Inc.

Securities Class Action

  • Date:
  • 3/4/2025
  • Company Name:
  • Revance Therapeutics, Inc.
  • Stock Symbol:
  • RVNC
  • Class Period:
  • FROM 2/29/2024 TO 12/6/2024
  • Status:
  • Filed
  • Filing Date:
  • 1/3/2025
  • Court:
  • U.S. District Court: Middle District of Tennessee

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQ:RVNC) in the United States District Court for the Middle District of Tennessee on behalf of all persons and entities who purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the “Class Period”). Investors have until March 4, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, the complaint alleges that Defendants failed to disclose to investors that: (1) Revance was in material breach of the Distribution Agreement; (2) the foregoing subjected the Company to an increased risk of litigation, as well as monetary and reputational harm; (3) all the foregoing increased the risk that the Tender Offer would be delayed and/or amended; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
 
If you purchased or otherwise acquired Revance shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.

Contact Instructions
Please contact Brandon Walker by email at investigations@bespc.com with any questions about this case.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Revance Therapeutics. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: